| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-02-29 | Immunovia (Sweden) undisclosed multinational life science company | Immunovia’s IMMray™ SLE-d (IMMray™systemic lupus erythematosus biomarker signatures) | systemic lupus erythematosus (SLE) | collaboration |
Autoimmune diseases - Diagnostic | Collaboration agreement |
| 2016-02-29 | Txcell (France) | process industrialization laboratories | opening of new premises |
Opening of new premises | ||
| 2016-02-29 | Veloxis Pharmaceuticals (Denmark) | nomination |
Transplantation - Renal diseases - Kidney diseases | Nomination | ||
| 2016-02-26 | Swedish Orphan Biovitrum - SOBI (Sweden) | resignation nomination |
Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2016-02-26 | Immunomedics (USA - NJ) UCB (Belgium) | epratuzumab | R&D licensing |
Termination of the agreement | ||
| 2016-02-25 | Esteve (Spain) Universitat Autònoma de Barcelona (Spain) | EGT-201, EGT-301 | mucopolysaccharidosis type II (Hunter's syndrome), mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) | R&D |
Rare diseases - Genetic diseases | R&D agreement |
| 2016-02-25 | Baxalta (USA - IL) Precision BioSciences (USA - NC) | allogeneic chimeric antigen receptor (CAR) T cell therapies for up to six targets | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2016-02-25 | Cobra Biologics (Sweden) Centre for Process Innovation (CPI) (UK) | industrial manufacturing platform for adeno-associated virus (AAV) production | collaboration production manufacturing |
Technology - Services | Collaboration agreement | |
| 2016-02-24 | Bayer Healthcare (Germany) | nomination |
Nomination | |||
| 2016-02-24 | Prothena (Ireland) | nomination |
Nomination | |||
| 2016-02-23 | Pierre Fabre laboratories (France) Plasticell (UK) | plant-based products enhancing the metabolic function of brown adipose tissue | diabetes, obesity | collaboration R&D |
Metabolic diseases | Collaboration agreement |
| 2016-02-23 | Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA) | clinical trials unit | opening of new premises |
Cancer - Oncology | Opening of new premises | |
| 2016-02-23 | Myokardia (USA - CA) | resignation |
Cardiovascular diseases | Resignation | ||
| 2016-02-23 | Reneuron (UK) | opening of new premises | Regenerative Medicine | Opening of new premises | ||
| 2016-02-23 | 4D Molecular Therapeutics (USA - CA) Choroideremia Research Foundation | gene therapy product optimized for intravitreal administration | choroideremia | development | Rare diseases - Genetic diseases - Ophtalmological diseases (USA - MA) | Development agreement |
| 2016-02-22 | ALK Abello (Denmark) | resignation |
Allergic diseases | Resignation | ||
| 2016-02-22 | Aptuit (UK) Icagen (USA - NC) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2016-02-18 | Axxam (Italy) Neomed (Canada) | small molecule agonists of FFA4 (also known as GPR120) | R&D collaboration |
Metabolic diseases - Inflammatory diseases | R&D agreement | |
| 2016-02-18 | AvroBio (USA - MA) | nomination | Cancer - Oncology - Rare diseases - Genetic diseases | Nomination | ||
| 2016-02-17 | Eisai (Japan) PIQUR Therapeutics (Switzerland) | Halaven® (Eribulin) and PQR309 | triple-negative breast cancer (TNBC). | R&D clinical research |
Cancer - Oncology | R&D agreement |
